Apidra (insulin glulisine) - Sanofi Canada
Apidra (insulin glulisine) - Sanofi Canada
Apidra (insulin glulisine) - Sanofi Canada
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
gender did not show differences in safety and efficacy between <strong>insulin</strong> <strong>glulisine</strong> and other shortacting<br />
<strong>insulin</strong> formulations.<br />
Hepatic Insufficiency: The effect of hepatic impairment on the pharmacokinetics of <strong>insulin</strong><br />
<strong>glulisine</strong> has not been studied. However, some studies with human <strong>insulin</strong> have shown increased<br />
circulating levels of <strong>insulin</strong> in patients with liver failure (see WARNINGS AND<br />
PRECAUTIONS).<br />
Race: Information on the effect of race on the pharmacokinetics of <strong>insulin</strong> <strong>glulisine</strong> is not<br />
available.<br />
Renal Insufficiency: Studies with human <strong>insulin</strong> have shown increased circulating levels of<br />
<strong>insulin</strong> in patients with renal failure. In a study performed in 24 non-diabetic subjects covering a<br />
wide range of renal function (CrCl>80mL/min; 30-50mL/min;